Stock Information. Stock Quote & Chart · Investor FAQs · Contact. Investors. Overview. Stock Quote. NASDAQ: EDIT. $5.60. Change; +0.11 (0.00%): Volume ...
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual ...
People also ask
What is EDIT 101?
What is EDIT 301?
When did Editas Medicine go public?
What does Editas medicine do?
We produce a suite of effective investor relations tools to disclose accurate IR information to institutional and retail investors.
Find annual and quearterly earnings data for Editas Medicine, Inc. Common Stock (EDIT) including earnings per share, earnings forecasts at Nasdaq.com.
(Nasdaq: EDIT), a leading genome editing company ... edited medicines and ex vivo gene edited ... Editas Medicine Investor Relations. (617) 401-9052. ir@editasmed.
Find the latest institutional holdings data for Editas Medicine, Inc. Common Stock (EDIT) including shareholders, ownership summaries, ...
The Investor Relations website contains information about Prime Medicine, Inc.'s business for stockholders, potential investors, and financial analysts.
Feb 29, 2024 · I would now like to turn the call over to Cristi Barnett, Corporate Communications and Investor Relations at Editas Medicine. ADVERTISEMENT.
Investor Relations · ~$10 BILLIONCumulative Shareholder Distributions · +27 PERCENTEarnings per Share Growth · 110 PERCENTTotal Shareholder Return.
View/edit your profile information. My Dashboard. View your dashboard. Logout. Logout of your account. Investor Relations. We help maximize humanity's ...